Abstract

Kartik G. Jadhav*, Shaikh Sameer Shaikh Farid, Syed Nabeel Ahmad, Rathod Ashwin Datta and Syed Saqlain Syed Saleem

ABSTRACT

Millions of people worldwide suffer with psoriasis, a chronic inflammatory skin illness caused by the immune system that is typified by erythematous plaques covered in silvery scales. Targeting certain cytokines and immunological pathways, biologic medicines have become essential in the management of moderate to severe psoriasis, despite the availability of many other therapy alternatives. This thorough analysis summarizes the state of knowledge about the pathogenesis of psoriasis, conventional treatments, and the development of biologic medicines. The mechanisms of action, clinical effectiveness, and safety profiles of important biologic medicines, such as PDE4 inhibitors, IL-17 and IL-23 inhibitors, TNF-alpha inhibitors, and IL-12/23 inhibitors, are covered. Comparative efficacy, long-term safety concerns, patient outcomes, and potential avenues for future biologic treatment research are highlighted. The purpose of this review is to give researchers and physicians a thorough understanding to enhance treatment approaches and enhance psoriasis management results.